SecBot SecBot
SC 13G/A ·Filed Nov 5, 2026

NAMS

NewAmsterdam Pharma Co N.V.
NEUTRAL
Impact 2/10
Horizonimmediate Processed11d 14h ago SEC0000315066-26-002799
Passive stake amendment
Actionable Insight • Neutral

Fidelity's marginal increase is routine portfolio rebalancing by a passive holder. Monitor future 13G filings for any material changes in stake size or a conversion to 13D, which would signal activist intent.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$18.89
T+0 close · Nov 5, 2026 · via day close
Latest settled
+5.72%
T+5 · $19.97
Vs SPY
+2.43%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $18.89entry
  2. T+1 · 11d ago +0.05%α −0.26% · $18.90
  3. T+5 · 5d ago +5.72%α +2.43% · $19.97
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

FMR LLC (Fidelity) filed an amended Schedule 13G reporting beneficial ownership of 11,941,763 common shares of NewAmsterdam Pharma (NAMS) as of September 30, 2026, representing 10.0% of shares outstanding. This is an increase from the prior filing (August 2026) which reported 11,931,218 shares (10.0%), reflecting a net addition of approximately 10,545 shares. The filing remains a passive stake with no change in control intent.

Key Financial Metrics

Stake
10%
Investor
FMR LLC
Investor Type
mutual fund

Key Facts

  • FMR LLC (Fidelity) reported beneficial ownership of 11,941,763 shares of NewAmsterdam Pharma common stock as of September 30, 2026.
  • The stake represents 10.0% of the outstanding shares.
  • This is an increase of approximately 10,545 shares from the prior filing (11,931,218 shares as of June 30, 2026).
  • The filing is a passive Schedule 13G/A, indicating no intent to change or influence control of the issuer.
  • Fidelity Management & Research Company LLC is the entity that beneficially owns 5% or greater of the outstanding shares.

Financial Impact

Fidelity's stake increased by approximately 10,545 shares, valued at roughly $0.2M based on a $2.4B market cap and 10.0% stake (implied share price ~$20.10).

ownership percentage

Risk Factors

  • No material risks identified from this routine passive stake update.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0000315066-26-002799
Document: 0000315066-26-002799-index-headers.html0000315066-26-002799
Document: 0000315066-26-002799-index.html0000315066-26-002799
Document: 0000315066-26-002799.txt0000315066-26-002799

Track record

8 reports on NAMS

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +7.23% at T+5 after the Sep 22, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Viewing Entry $18.89 to $18.90 Now $19.46 +3.02% ▲ +0.05% −0.26% vs SPY
  2. Nov 4, 202612d ago Press Release Neutral 5/10 Entry $20.93 to $18.89 Now $19.46 −7.02% ▼ −9.75% −5.34% vs SPY
  3. Sep 29, 20266w ago 8-K Neutral 4/10 Entry $23.81 to $24.32 Now $19.46 −18.27% ▲ +2.14% +2.35% vs SPY
  4. Sep 22, 20267w ago SC 13D/A Bullish 5/10 Entry $22.68 to $22.74 Now $19.46 −14.20% ▲ +0.26% +0.35% vs SPY
  5. Sep 15, 20268w ago Insider Buy Bullish 5/10 Entry $21.18 to $21.93 Now $19.46 −8.12% ▲ +3.54% +2.41% vs SPY
  6. Aug 5, 202614w ago 8-K Bullish 7/10 Entry $27.42 to $27.67 Now $19.46 −29.03% ▲ +0.91% +1.07% vs SPY
  7. Jul 24, 202616w ago 8-K Bullish 7/10 Entry $29.64 to $30.22 Now $19.46 −34.35% ▲ +1.96% +1.94% vs SPY
  8. Apr 8, 202631w ago Press Release Neutral 5/10 Entry $34.01 to $35.07 Now $19.46 −42.78% ▲ +3.12% +2.54% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 5h 48m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026